RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS

RedHill Biopharma Ltd.

21 Ha'arba'a Street
Tel Aviv 64739
972 3 541 3131

Full Time Employees74

Key Executives

NameTitlePayExercisedYear Born
Mr. Dror Ben-AsherCo-Founder, Chairman & CEO333.32kN/A1966
Mr. Micha Ben-ChorinChief Financial Officer223.8kN/A1969
Mr. Gilead RadayChief Operating Officer302.2kN/A1975
Dr. Reza FathiSr. VP of R&D267.01kN/A1955
Mr. Guy GoldbergChief Bus. Officer221.4kN/A1976
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILS.


RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions. Its clinical-stage development programs include TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with an ongoing confirmatory Phase III study and successful results from a first Phase III study; RHB-104 with an ongoing first Phase III study for Crohn's disease and a planned pivotal Phase III study for nontuberculous mycobacteria infections; BEKINDA (RHB-102) with positive results from a Phase III study in acute gastroenteritis and gastritis, and positive results from a Phase II study in IBS-D; YELIVA (ABC294640), a SK2 selective inhibitor, targeting multiple oncology, inflammatory, and gastrointestinal indications with an ongoing Phase IIa study for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; and RHB-107 (MESUPRON), a Phase II-stage serine protease inhibitor targeting gastrointestinal and other solid tumor cancers. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Corporate Governance

RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.